Agios Pharmaceuticals Inc Investor Event to Review AG-270 Phase 1 Data and Research Transcript
Hello. How's everybody doing? Holly, Kendra, do you want me to start? I do what you guys tell me to do. So okay. How's everybody doing? Good to see you, good to see you. Thanks for being with us tonight. So we are very pleased to be here to focus on and talk about the AG-270 MAT2A inhibitor data tonight. I know it's been a long-awaited moment to dig into this data set. So hopefully, some of you had a chance to go through the presentations today. But we'll spend this evening on the topic for as long as you want to stay here with us and talk about it.
These are the forward-looking statements. I'm not going to read the whole thing, you know what they are. I just wanted to kick off the discussion with -- I have 2 slides. One is to introduce the presenters to you. Some of you, I think, have had the pleasure of interacting with Kevin Marks, our Head of Biology in the past. So Kevin is going to present the biology around the molecule and the program tonight. We then have Chris Bowden, all of you know him, our Chief Medical Officer, who
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
